Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gladys Morrison

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Gynecologic Oncology|November 12, 2015
Chemotherapy-induced peripheral neuropathy: Current status and progressJamie R Brewer, Gladys Morrison, M Eileen Dolan, et al.
Stem Cell Research|January 17, 2016
Evaluation of inter-batch differences in stem-cell derived neuronsGladys Morrison, Cong Liu, Claudia Wing, et al.
Oncotarget|February 1, 2018
Discovering drugs to overcome chemoresistance in ovarian cancers based on the cancer genome atlas tumor transcriptome profileFan Wang, Jeremy T-H Chang, Zhenyu Zhang, et al.
Cancers|March 6, 2021
Facilitating Drug Discovery in Breast Cancer by Virtually Screening Patients Using In Vitro Drug Response ModelingRobert F Gruener, Alexander Ling, Ya-Fang Chang, et al.
Genome Research|August 30, 2017
Discovering novel pharmacogenomic biomarkers by imputing drug response in cancer patients from large genomics studiesPaul Geeleher, Zhenyu Zhang, Fan Wang, et al.
Breast Cancer Research and Treatment|February 21, 2014
Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistanceGladys Morrison, Xiaoyong Fu, Martin Shea, et al.
Neurobiology of Pain (Cambridge, Mass.)|January 8, 2020
The NMDAR modulator NYX-2925 alleviates neuropathic pain via a Src-dependent mechanism in the mPFCGladys Morrison, Marina N Asiedu, Jessica M Priebe, et al.
Oncotarget|May 26, 2016
Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patientsGladys Morrison, Divya Lenkala, Bonnie LaCroix, et al.
Breast Cancer Research : BCR|November 30, 2011
Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivationYen-Chao Wang, Gladys Morrison, Ryan Gillihan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2026
Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met-Targeting Antibody-Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction CancerJohn H Strickler, Judith Raimbourg, Jonathan E Cohen, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Gynecologic Oncology|November 12, 2015
Chemotherapy-induced peripheral neuropathy: Current status and progressJamie R Brewer, Gladys Morrison, M Eileen Dolan, et al.
Stem Cell Research|January 17, 2016
Evaluation of inter-batch differences in stem-cell derived neuronsGladys Morrison, Cong Liu, Claudia Wing, et al.
Oncotarget|February 1, 2018
Discovering drugs to overcome chemoresistance in ovarian cancers based on the cancer genome atlas tumor transcriptome profileFan Wang, Jeremy T-H Chang, Zhenyu Zhang, et al.
Cancers|March 6, 2021
Facilitating Drug Discovery in Breast Cancer by Virtually Screening Patients Using In Vitro Drug Response ModelingRobert F Gruener, Alexander Ling, Ya-Fang Chang, et al.
Genome Research|August 30, 2017
Discovering novel pharmacogenomic biomarkers by imputing drug response in cancer patients from large genomics studiesPaul Geeleher, Zhenyu Zhang, Fan Wang, et al.
Breast Cancer Research and Treatment|February 21, 2014
Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistanceGladys Morrison, Xiaoyong Fu, Martin Shea, et al.
Neurobiology of Pain (Cambridge, Mass.)|January 8, 2020
The NMDAR modulator NYX-2925 alleviates neuropathic pain via a Src-dependent mechanism in the mPFCGladys Morrison, Marina N Asiedu, Jessica M Priebe, et al.
Oncotarget|May 26, 2016
Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patientsGladys Morrison, Divya Lenkala, Bonnie LaCroix, et al.
Breast Cancer Research : BCR|November 30, 2011
Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivationYen-Chao Wang, Gladys Morrison, Ryan Gillihan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2026
Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met-Targeting Antibody-Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction CancerJohn H Strickler, Judith Raimbourg, Jonathan E Cohen, et al.
Pageof 2